Selected article for: "life cycle and MHC class"

Author: Austin Nguyen; Julianne K David; Sean K Maden; Mary A Wood; Benjamin R Weeder; Abhinav Nellore; Reid F Thompson
Title: Human leukocyte antigen susceptibility map for SARS-CoV-2
  • Document date: 2020_3_26
  • ID: k3y8tpps_10
    Snippet: We were further interested in whether certain regions of the SARS-CoV-2 proteome showed differential presentation by the MHC class I pathway. Accordingly, we surveyed the distribution of antigen presentation capacity across the entire proteome, highlighting its most conserved peptide sequences (Figure 4 ). Throughout the entire proteome, HLA-A and HLA-C alleles exhibited the relative largest and smallest capacity to present SARS-CoV-2 antigens, r.....
    Document: We were further interested in whether certain regions of the SARS-CoV-2 proteome showed differential presentation by the MHC class I pathway. Accordingly, we surveyed the distribution of antigen presentation capacity across the entire proteome, highlighting its most conserved peptide sequences (Figure 4 ). Throughout the entire proteome, HLA-A and HLA-C alleles exhibited the relative largest and smallest capacity to present SARS-CoV-2 antigens, respectively. However each of the three major class I genes exhibited a very similar pattern of peptide presentation across the proteome (Supplementary Figure S3) . We additionally note that peptide presentation appears to be independent of estimated time of peptide production during viral life cycle, with indistinguishable levels of peptide presentation of both early and late SARS-CoV-2 peptides (Supplementary Figure S4 ). CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • antigen presentation and SARS peptide: 1, 2, 3
    • antigen presentation and SARS proteome: 1, 2, 3, 4, 5, 6, 7
    • antigen presentation and similar pattern: 1
    • antigen presentation and viral life cycle: 1, 2, 3
    • antigen presentation capacity and SARS antigen: 1
    • antigen presentation capacity and SARS proteome: 1
    • cc NC ND International license and SARS antigen: 1
    • cc NC ND International license and SARS peptide: 1, 2, 3, 4, 5
    • cc NC ND International license and SARS proteome: 1, 2
    • cc NC ND International license and similar pattern: 1, 2, 3, 4, 5
    • entire proteome and SARS antigen: 1
    • entire proteome and SARS peptide: 1, 2
    • entire proteome and SARS proteome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • estimate time and similar pattern: 1, 2, 3
    • International license and SARS peptide: 1, 2, 3, 4, 5, 6, 7, 8
    • International license and SARS proteome: 1, 2
    • International license and similar pattern: 1, 2, 3, 4, 5, 6, 7
    • life cycle and SARS peptide: 1, 2, 3
    • life cycle and SARS proteome: 1, 2, 3, 4, 5, 6